Placenta previa and placental abruption: painless vs painful bleeding differentiation

LS
By Lindsay Smith, AGPCNP
Updated October 7, 2026

Reviewed for clinical accuracy · Methodology: NIH, NCBI, AANP guidelines

Antepartum hemorrhage – bleeding during the second or third trimester before delivery – is one of the most dangerous and high-stakes clinical scenarios in obstetric nursing. The two leading causes are placenta previa and placental abruption. Together they account for the vast majority of serious antepartum hemorrhage cases, and both carry significant risk of maternal and fetal mortality if not managed correctly.

These two conditions are paired constantly in maternity nursing courses and NCLEX-style questions, and for good reason: they share the same presenting complaint (vaginal bleeding in the third trimester) yet have opposite pathophysiology, opposite physical exam findings, and substantially different management priorities. Understanding how to tell them apart – and what to do for each – is a non-negotiable clinical competency.

Quick comparison: placenta previa vs placental abruption

This table is the core of the article. Use it as your primary study reference when differentiating these two conditions.

Feature Placenta previa Placental abruption
Definition Placenta implants in the lower uterine segment, partially or completely covering the internal cervical os Premature separation of a normally implanted placenta from the uterine wall before delivery
Mechanism Abnormal implantation site – placenta physically obstructs the birth canal Shearing force or vascular disruption causes retroplacental hematoma formation
Bleeding character Bright red, painless, may be sudden and profuse Dark red; may be concealed (no visible bleeding) or revealed; amount may not reflect true blood loss
Onset of bleeding Often spontaneous, no triggering event Often associated with trauma, cocaine use, hypertension, or sudden uterine decompression
Pain Painless – classic hallmark Painful – sudden, severe abdominal pain; classic hallmark
Uterine tone Soft, non-tender uterus Rigid, board-like uterus; uterine hypertonicity; may have persistent contractions
Fundal palpation Soft, non-tender – but do not perform bimanual or digital vaginal exam (contraindicated) Rigid/tender on palpation; bimanual exam also contraindicated if previa not ruled out
Fetal presentation Malpresentation common (oblique, transverse, breech) due to placenta occupying lower segment Usually vertex unless abruption is severe and fetal status is compromised
Fetal monitoring Non-reassuring FHR may develop if hemorrhage is significant; often initially stable Late decelerations, prolonged decelerations, or sinusoidal pattern from fetal hypoxia and anemia
Maternal hemorrhage risk High – especially with complete previa or placenta accreta spectrum High – concealed hemorrhage is insidious; DIC is a major risk
DIC risk Lower – unless massive hemorrhage or placenta accreta High – retroplacental clot releases thromboplastin, triggering consumptive coagulopathy
Diagnosis Transabdominal ultrasound first; transvaginal ultrasound is safe and definitive – never digital vaginal exam Clinical diagnosis; ultrasound sensitivity was only 24% in one study (Glantz 2002), so a normal scan does not rule abruption out
Delivery route Cesarean for placenta previa; with a low-lying placenta, a trial of labor may be considered depending on how far the placental edge lies from the os Emergency cesarean if fetal compromise or severe abruption; vaginal delivery may be possible for mild grades

Placenta previa

Definition and types

Placenta previa occurs when the placenta implants in the lower uterine segment, covering part or all of the internal cervical os. As the lower uterine segment grows and the cervix begins to efface in late pregnancy, the implanted placenta cannot stretch to accommodate – the vessels tear, and bleeding results.

Current classification, established by the 2014 Fetal Imaging Workshop consensus (NICHD, SMFM, ACOG, AIUM, and ACR) and used by ACOG since, has only two categories:

  • Placenta previa: the placenta overlies or abuts the internal cervical os to any degree. Cesarean delivery is required.
  • Low-lying placenta: the placental edge lies within 2 cm of the internal os but does not reach or cover it. Many resolve as the lower uterine segment develops; repeat ultrasound in the third trimester is standard. A placental edge 2 cm or more from the os supports a trial of labor; an edge 1–2 cm from the os is a gray zone where management is individualized.

The older four-tier terminology – complete (total), partial, marginal, and low-lying – has been formally retired, because “partial” and “marginal” could not be applied reproducibly as the cervix dilated. Those terms still circulate in textbooks and appear in NCLEX item banks, so recognize them: complete and partial previa both fall under today’s “placenta previa,” while marginal previa is now classified as a low-lying placenta when the edge does not reach the os.

Risk factors

  • Prior cesarean delivery or uterine surgery (most significant risk factor – scarring disrupts normal implantation)
  • Advanced maternal age
  • Multiparity
  • Prior placenta previa
  • Multiple gestation (twins, triplets)
  • Smoking
  • Cocaine use
  • Uterine anomalies (fibroids, septum)
  • Assisted reproductive technology (IVF)

Classic presentation

The classic presentation is painless bright red vaginal bleeding in the second or third trimester, often sudden and without warning. There is no associated abdominal pain, no uterine contractions (unless labor has begun), and the uterus is soft on palpation. The bleed may stop spontaneously, recur, and worsen as pregnancy advances.

The first episode of bleeding may be relatively small – a “sentinel bleed.” Subsequent bleeds are often more severe.

Diagnosis

  • Transabdominal ultrasound: first-line, identifies placental location in most cases
  • Transvaginal ultrasound (TVUS): safe, well-tolerated, and more accurate than transabdominal for posterior placenta and for measuring the exact distance from the placental edge to the internal os – preferred for definitive diagnosis
  • Digital vaginal exam: absolutely contraindicated until placenta previa has been excluded by ultrasound. A digital exam in a woman with undiagnosed complete previa can precipitate catastrophic hemorrhage. This is a high-yield NCLEX red flag item.
  • Bimanual exam: absolutely contraindicated for the same reason.

Management

Expectant management (for preterm, hemodynamically stable patients):

  • Hospitalization for the first episode of bleeding; outpatient management may be considered in stable patients without active bleeding
  • Pelvic rest – no intercourse, no vaginal exams, no douching
  • Continuous electronic fetal monitoring during active bleeding
  • IV access (two large-bore IVs)
  • Type and screen (or crossmatch if bleeding is significant)
  • Betamethasone 12 mg IM ×2 doses, 24 hours apart, to accelerate fetal lung maturity. A single course is recommended from 24 0/7 through 33 6/7 weeks when delivery is anticipated within 7 days, and from 34 0/7 through 36 6/7 weeks for patients who have not already had a course
  • Tocolysis (terbutaline) may be used cautiously to suppress contractions and allow betamethasone to work – NOT for ongoing hemorrhage
  • Magnesium sulfate for fetal neuroprotection if delivery is expected before 32 weeks

Delivery:

  • Placenta previa (placenta overlying or abutting the os): planned cesarean at 36 0/7 to 37 6/7 weeks gestation if stable, or emergent if hemorrhage
  • Placental edge 2 cm or more from the os on repeat third-trimester ultrasound: trial of labor is reasonable. An edge 1–2 cm from the os is a gray zone managed case by case, and delivery timing is individualized
  • Placenta accreta spectrum (when placenta invades myometrium) should be suspected in any patient with prior cesarean and anterior previa – requires multidisciplinary planning and potential hysterectomy

Nursing interventions

  1. No vaginal examinations – post a clear sign at the bedside. This includes speculum exams unless ordered and previa has been ruled out.
  2. Establish two large-bore IV lines (18 gauge or larger)
  3. Continuous electronic fetal monitoring
  4. Give oxygen for maternal hypoxia or hemodynamic instability; ACOG (Clinical Practice Guideline No. 10, 2025) recommends against routine maternal oxygen solely for an abnormal fetal heart rate tracing when the patient is not hypoxic
  5. Obtain CBC, type and crossmatch, coagulation studies, BMP
  6. Monitor pad count and weigh pads to quantify blood loss
  7. Bed rest – ambulation restrictions based on severity and gestational age
  8. Administer betamethasone as ordered
  9. Prepare for emergency cesarean if hemorrhage escalates
  10. Emotional support – patients are often terrified and facing prolonged hospitalization

Placental abruption

Definition and grades

Placental abruption (also called abruptio placentae) is the premature separation of a normally implanted placenta from the uterine wall before delivery of the fetus. Blood accumulates between the placenta and the uterine wall – a retroplacental hematoma – disrupting uteroplacental blood flow and threatening fetal oxygen delivery.

Most nursing texts grade abruption clinically from 0 to 3:

  • Grade 0: No symptoms; diagnosed retrospectively after delivery by finding a retroplacental clot
  • Grade 1 (mild): Mild vaginal bleeding; no fetal distress; no maternal hemodynamic compromise; uterine irritability
  • Grade 2 (moderate): Moderate to heavy bleeding; uterine hypertonicity; fetal distress present; maternal tachycardia; no maternal shock
  • Grade 3 (severe): Heavy bleeding (may be concealed); fetal death; maternal shock; coagulopathy (DIC) common

The Sher classification (Sher and Statland, 1985), often quoted alongside it, defines its grade III by fetal death and splits it into IIIA (no coagulopathy) and IIIB (overt coagulopathy). Sher noted that severe maternal coagulopathy is uncommon while the fetus is still alive, so fetal death in abruption should prompt immediate coagulation testing.

Risk factors

  • Hypertensive disorders of pregnancy (preeclampsia, chronic hypertension) – most common risk factor
  • Abdominal trauma (motor vehicle accident, assault, falls) – even minor trauma can trigger abruption
  • Cocaine use – causes intense vasoconstriction, precipitating vessel rupture
  • Cigarette smoking
  • Prior abruption (recurrence risk 10–15% after one episode, up to 25% after two)
  • Premature rupture of membranes (PROM) – sudden uterine decompression
  • Multiple gestation
  • Polyhydramnios – rapid loss of amniotic fluid
  • Advanced maternal age
  • Thrombophilias (antiphospholipid syndrome)
  • Short umbilical cord

Classic presentation

The classic presentation is sudden, severe abdominal pain with dark red vaginal bleeding and a rigid, board-like abdomen. Uterine hypertonicity – the uterus does not relax between contractions, or there are no discrete contractions at all – is the hallmark physical finding.

Fetal heart rate patterns deteriorate as placental separation reduces oxygen delivery: late decelerations, prolonged decelerations, severe variable decelerations, or a sinusoidal pattern indicating severe fetal anemia.

Concealed vs revealed hemorrhage: In up to about 20% of abruptions, the blood does not escape vaginally – it remains trapped behind the placenta. This is concealed hemorrhage. The absence of visible bleeding does not mean the patient is not bleeding significantly. Uterine hypertonicity, pain, and fetal distress without obvious external blood loss should raise immediate suspicion for concealed abruption. The degree of clinical deterioration (maternal shock, fetal compromise) may far exceed what the visible blood loss would predict.

DIC risk

Abruption is one of the leading obstetric triggers of disseminated intravascular coagulation (DIC). The mechanism: placental separation releases tissue thromboplastin (factor III) into the maternal circulation in large quantities, activating the coagulation cascade diffusely. Clotting factors and platelets are consumed faster than they can be replaced – consumptive coagulopathy.

Critical monitoring parameters:

  • Fibrinogen: a level below 200 mg/dL is the critical threshold – it predicts progression to severe coagulopathy and is an early, sensitive marker of DIC in this setting (normal pregnancy fibrinogen is 400–600 mg/dL, so even “normal” values for non-pregnant adults may represent significant depletion)
  • Platelet count, PT, aPTT, D-dimer
  • Signs of DIC: oozing from IV sites, petechiae, inability to form clots

For a detailed DIC nursing reference, see the DIC nursing reference.

Management

Management depends on gestational age, fetal status, and severity of hemorrhage.

Grade 1 (mild, stable, remote from term):

  • Hospitalization, continuous monitoring
  • May attempt to prolong pregnancy with fetal lung maturity treatment (betamethasone)
  • Close surveillance with repeat ultrasound

Grade 2–3 (moderate–severe) or fetal compromise:

  • Emergency delivery – cesarean section is the most common route, but rapid vaginal delivery may be attempted if the patient is fully dilated and delivery is imminent
  • Aggressive IV fluid resuscitation with two large-bore IVs
  • Blood product transfusion (see medications table below)
  • Continuous fetal monitoring until delivery
  • DIC surveillance and treatment

Fetal death (Grade 3):

  • Vaginal delivery may be preferred over cesarean when the fetus has died, to minimize maternal surgical risk
  • DIC management is the primary concern

Nursing interventions

  1. Establish two large-bore IV lines (16 or 18 gauge) immediately
  2. Initiate continuous electronic fetal monitoring
  3. Give oxygen by face mask for maternal hypoxia, hypotension, or shock per protocol (many NCLEX items still key 8–10 L/min by face mask; ACOG now advises against oxygen given only to treat the fetal heart rate tracing in a well-oxygenated patient)
  4. Draw stat CBC, fibrinogen, PT/aPTT, type and crossmatch, BMP, DIC panel
  5. Monitor fibrinogen level serially – this is the most sensitive early indicator of coagulopathy
  6. Quantify blood loss; weigh pads; monitor for signs of concealed hemorrhage (pain and fetal distress disproportionate to visible bleeding)
  7. Position in left lateral tilt to relieve aortocaval compression
  8. Prepare blood products per orders: packed red blood cells (PRBCs), fresh frozen plasma (FFP), cryoprecipitate, platelets
  9. Insert urinary catheter; monitor urine output (target ≥30 mL/hr – oliguria signals hemorrhagic shock)
  10. Prepare for emergency cesarean: notify OR, anesthesia, neonatology
  11. Monitor for signs of DIC: petechiae, oozing from IV sites, hematuria, prolonged clotting

Rh status and the Kleihauer-Betke test

Check Rh D status on every patient with antepartum bleeding from either cause. ACOG Practice Bulletin No. 181 lists antepartum hemorrhage and abdominal trauma among the events that call for anti-D immune globulin in unsensitized Rh D-negative patients, given within 72 hours of the event. A standard 300-microgram dose covers up to 30 mL of fetal whole blood (15 mL of fetal red cells).

The Kleihauer-Betke test (or flow cytometry) measures how much fetal blood has entered the maternal circulation. Its nursing relevance is dosing: when a large fetal-maternal hemorrhage is possible, as with abruption or trauma, the result tells the team whether more than one vial of anti-D is needed. It does not diagnose abruption, and a negative result does not rule abruption out.

Nursing priority comparison

Nursing priority Placenta previa Placental abruption
Highest priority nursing action No vaginal exams – post sign, alert all providers IV access ×2, continuous fetal monitoring, stat coagulation labs
IV access Two large-bore IVs (18 gauge or larger) Two large-bore IVs (16–18 gauge) – place immediately
Labs to draw CBC, type and crossmatch, coagulation studies CBC, fibrinogen, PT/aPTT, type and crossmatch, DIC panel – fibrinogen is the priority
Fetal monitoring Continuous EFM; may be initially reassuring Continuous EFM; anticipate late decelerations, prolonged decels, sinusoidal
Pelvic examination Absolutely contraindicated – digital or bimanual exam can cause fatal hemorrhage Contraindicated if previa not yet excluded; do not perform until imaging complete
Oxygen For maternal hypoxia or instability For maternal hypoxia, hypotension, or shock; not routinely for the fetal tracing alone (ACOG CPG 10, 2025)
Position Bed rest; left lateral if fetal compromise Left lateral tilt to relieve aortocaval compression
Urinary catheter If delivery is anticipated or hemorrhage is severe Insert early – urine output ≥30 mL/hr is the target; oliguria = shock
Blood products Crossmatch and hold; transfuse if hemodynamically unstable Prepare PRBCs, FFP, cryoprecipitate, platelets – DIC requires replacement of all factors
Cesarean preparation Plan for scheduled cesarean at 36 0/7–37 6/7 weeks, or emergency cesarean if hemorrhage escalates Prepare for emergency cesarean immediately in Grade 2–3 or fetal compromise
Patient education Pelvic rest, activity restrictions, signs to report immediately Limited – emergent situation; focus on family support and clear communication

Medications

Medication Drug class Indication Dose / key points Nursing considerations
Betamethasone Corticosteroid Fetal lung maturity – stimulates surfactant production; reduces risk of respiratory distress syndrome, IVH, necrotizing enterocolitis 12 mg IM ×2 doses, 24 hours apart. Give when delivery is anticipated within 7 days between 24 0/7 and 33 6/7 weeks; also recommended between 34 0/7 and 36 6/7 weeks for patients who have not already received a course (ACOG/SMFM). Repeat or serial courses beyond two are not recommended Administer deep IM (gluteal). May transiently elevate maternal blood glucose – monitor in diabetic patients. Document time of first dose to ensure second dose is given on schedule.
Terbutaline Beta-2 agonist tocolytic Short-term uterine relaxation to allow betamethasone to work; not used for long-term tocolysis 0.25 mg SQ q20–30 min ×3 doses; or 2.5–5 mcg/min IV infusion Monitor maternal HR (tachycardia is common side effect), blood pressure, blood glucose. Hold if maternal HR >130 bpm. Contraindicated in active hemorrhage – do not use to suppress contractions in ongoing abruption. FDA boxed warning (2011): injectable terbutaline must not be used for prolonged (beyond 48–72 hours) tocolysis, and oral terbutaline must not be used to prevent or treat preterm labor.
Magnesium sulfate CNS depressant / tocolytic Fetal neuroprotection (delivery before 32 weeks); also used for seizure prophylaxis in preeclampsia Neuroprotection: 4–6 g IV loading dose over 20–30 min, then 1–2 g/hr maintenance. Duration: until delivery or 12 hours Monitor for toxicity: loss of DTRs (first sign), respiratory depression (RR <12), urine output. Keep calcium gluconate at bedside as antidote. No serum target is set for neuroprotection; the 4–7 mEq/L range usually quoted applies to seizure prophylaxis.
Packed red blood cells (PRBCs) Blood product Replace oxygen-carrying capacity in hemorrhage; during active bleeding, transfuse by blood loss and hemodynamic status (massive transfusion protocol) rather than waiting for a hemoglobin value Typical unit: 250–350 mL; transfuse based on clinical status and hemoglobin Verify blood type and crossmatch; two-nurse verification before hanging. Monitor for transfusion reactions: fever, chills, back pain, hemoglobinuria. Each unit raises Hgb ~1 g/dL.
Fresh frozen plasma (FFP) Blood product Replace clotting factors in DIC or massive hemorrhage; use when PT/aPTT >1.5× normal Typical dose: 10–15 mL/kg; each unit ~250 mL Must be ABO compatible. Thaw time required (~20–30 min) – order early. Monitor for transfusion reaction and fluid overload.
Cryoprecipitate Blood product Replace fibrinogen and Factor VIII in DIC; indicated when fibrinogen <200 mg/dL Pool of 10 units (1 adult therapeutic dose); raises fibrinogen ~60–100 mg/dL ABO compatibility preferred. Used specifically for fibrinogen replacement when FFP alone is insufficient. Monitor fibrinogen levels post-transfusion.
Platelets Blood product Treat thrombocytopenia from DIC; transfuse if platelets <50,000/µL with active bleeding One apheresis unit or pool of 4–6 random donor units; raises platelets ~30,000–50,000/µL Transfuse as rapidly as tolerated. Monitor for transfusion reactions. Each apheresis unit raises platelet count ~30,000–50,000/µL in a 70 kg patient.

NCLEX tips

Tip 1: Painless vs painful bleeding – the single most tested discriminator The hallmark difference between previa and abruption is pain. Placenta previa: painless, bright red bleeding. Placental abruption: painful, dark red bleeding with a rigid uterus. If the question says “painless,” think previa. If it says “sudden severe abdominal pain,” think abruption. This one distinction appears on nearly every OB NCLEX question involving antepartum hemorrhage.

Tip 2: Never perform a digital vaginal exam in suspected placenta previa This is the most commonly tested “what NOT to do” item in OB nursing. If a patient presents with painless third-trimester bleeding and placenta previa has not been excluded, no vaginal exam of any kind may be performed – not a speculum exam, not a digital exam, not a bimanual exam. The correct action is immediate ultrasound. Any NCLEX option that includes “perform a pelvic exam” in this clinical scenario is wrong.

Tip 3: Transvaginal ultrasound is safe in placenta previa – and preferred Students often assume that transvaginal ultrasound is contraindicated in placenta previa because “something is going in the vagina.” This is incorrect. The transvaginal probe does not reach the internal os and does not trigger hemorrhage. It is the standard diagnostic tool for confirming previa and measuring the distance from the placental edge to the os. Digital probing of the os is what is dangerous – not the ultrasound probe.

Tip 4: Fibrinogen is the critical DIC marker in abruption When an NCLEX question describes placental abruption and asks what lab value to monitor most closely, the answer is fibrinogen. A fibrinogen level below 200 mg/dL (in a pregnant patient who should have fibrinogen of 400–600 mg/dL) is the earliest and most sensitive indicator of consumptive coagulopathy. Watch for “normal” fibrinogen levels that are low for pregnancy despite looking unremarkable – 250 mg/dL is concerning in an obstetric patient even though it’s within the standard non-pregnant reference range.

Tip 5: Concealed abruption – blood loss exceeds visible bleeding In up to about 20% of abruptions, there is no external bleeding – the hematoma is trapped behind the placenta. NCLEX questions may describe severe abdominal pain, a rigid uterus, fetal distress, and maternal hypotension with minimal or no vaginal bleeding. Do not be reassured by the absence of visible blood. The clinical picture (pain, rigidity, fetal compromise) takes precedence. This is also why you must monitor urine output and hemodynamic trends – not just pad counts.

Tip 6: Bimanual exam is contraindicated in both conditions NCLEX will test whether students know that bimanual examination – not just digital vaginal exam – is contraindicated until previa is excluded. This applies to both conditions. In abruption, bimanual exam will not help the diagnosis and risks worsening hemorrhage.

Tip 7: Placenta previa always requires cesarean delivery When a question describes placenta previa (older items say “complete” or “total” previa) and asks about delivery planning, the answer is cesarean section – there is no clinical scenario in which vaginal delivery is safe when the placenta covers the os. The placenta physically obstructs the birth canal, and any attempt at vaginal delivery or labor augmentation risks catastrophic hemorrhage. This is tested in both direct knowledge questions and priority-setting scenarios.

Tip 8: Prioritize in the right order When presented with an NCLEX scenario involving antepartum hemorrhage, the priority sequence is: (1) assess airway/breathing/circulation, (2) establish IV access and begin fluid resuscitation, (3) apply continuous fetal monitoring, (4) draw coagulation labs, (5) prepare for delivery. Performing a vaginal exam is never the first action.

The two conditions in this article belong to a broader cluster of high-acuity OB content. For a complete obstetric nursing framework – including labor stages, fetal heart rate interpretation, hypertensive disorders of pregnancy, and full OB medication review – see the obstetric nursing reference.

Antepartum hemorrhage from placental abruption can transition to postpartum hemorrhage after delivery, particularly when DIC has depleted clotting factors. The postpartum hemorrhage nursing reference covers the 4 T’s framework, uterotonic medications, and quantitative blood loss management in detail.

DIC triggered by abruption is managed with blood product replacement – the principles are covered fully in the DIC nursing reference.

Hypertensive disorders of pregnancy (preeclampsia, HELLP syndrome) are the most common underlying risk factor for abruption. See the HELLP syndrome nursing reference for a focused review of that spectrum.

When fetal compromise is identified on electronic fetal monitoring – late decelerations, sinusoidal patterns, or prolonged decelerations – the neonatal nursing reference provides the immediate newborn assessment framework used after emergent delivery, including the Apgar scoring system.

Hemorrhagic shock from either condition follows the same physiologic trajectory covered in the shock nursing reference.

References

  1. Fetal Imaging Workshop Invited Participants. Fetal Imaging: Executive Summary of a Joint Eunice Kennedy Shriver National Institute of Child Health and Human Development, Society for Maternal-Fetal Medicine, American Institute of Ultrasound in Medicine, American College of Obstetricians and Gynecologists, American College of Radiology, Society for Pediatric Radiology, and Society of Radiologists in Ultrasound Fetal Imaging Workshop. Obstetrics and Gynecology. 2014;123(5):1070–1082. doi:10.1097/AOG.0000000000000245 (source of the current two-category previa / low-lying placenta nomenclature)
  2. American College of Obstetricians and Gynecologists. Medically Indicated Late-Preterm and Early-Term Deliveries. ACOG Committee Opinion No. 831. Obstetrics and Gynecology. 2021;138(1):e35–e39. doi:10.1097/AOG.0000000000004447 (replaces Committee Opinion No. 764, 2019)
  3. Oyelese Y, Ananth CV. Placental Abruption. Obstetrics and Gynecology. 2006;108(4):1005–1016. doi:10.1097/01.AOG.0000239439.04364.9a
  4. Ananth CV, Berkowitz GS, Savitz DA, Lapinski RH. Placental Abruption and Adverse Perinatal Outcomes. JAMA. 1999;282(17):1646–1651. PMID: 10553791
  5. Silver RM, Landon MB, Rouse DJ, et al. Maternal Morbidity Associated with Multiple Repeat Cesarean Deliveries. Obstetrics and Gynecology. 2006;107(6):1226–1232. PMID: 16738145
  6. McGoldrick E, Stewart F, Parker R, Dalziel SR. Antenatal Corticosteroids for Accelerating Fetal Lung Maturation for Women at Risk of Preterm Birth. Cochrane Database of Systematic Reviews. 2020;(12):CD004454. doi:10.1002/14651858.CD004454.pub4 (updates the 2017 Roberts review)
  7. Rouse DJ, Hirtz DG, Thom E, et al. A Randomized, Controlled Trial of Magnesium Sulfate for the Prevention of Cerebral Palsy. New England Journal of Medicine. 2008;359(9):895–905. doi:10.1056/NEJMoa0801187
  8. Association of Women’s Health, Obstetric and Neonatal Nurses (AWHONN). Quantification of Blood Loss: AWHONN Practice Brief Number 13. Journal of Obstetric, Gynecologic, and Neonatal Nursing. 2021;50(4):503–505. doi:10.1016/j.jogn.2021.04.007 (replaces the retired Practice Brief Number 1, 2015)
  9. Creanga AA, Berg CJ, Ko JY, et al. Maternal Mortality and Morbidity in the United States: Where Are We Now? Journal of Women’s Health. 2014;23(1):3–9. doi:10.1089/jwh.2013.4617
  10. Sher G, Statland BE. Abruptio Placentae with Coagulopathy: A Rational Basis for Management. Clinical Obstetrics and Gynecology. 1985;28(1):15–23. doi:10.1097/00003081-198528010-00003
  11. Glantz C, Purnell L. Clinical Utility of Sonography in the Diagnosis and Treatment of Placental Abruption. Journal of Ultrasound in Medicine. 2002;21(8):837–840. doi:10.7863/jum.2002.21.8.837
  12. Hull AD, Resnik R. Placenta Accreta and Postpartum Hemorrhage. Clinical Obstetrics and Gynecology. 2010;53(1):228–236. doi:10.1097/GRF.0b013e3181ce6aef
  13. Main EK, Goffman D, Scavone BM, et al. National Partnership for Maternal Safety: Consensus Bundle on Obstetric Hemorrhage. Obstetrics and Gynecology. 2015;126(1):155–162. doi:10.1097/AOG.0000000000000869 (co-published as Anesthesia and Analgesia. 2015;121(1):142–148)
  14. Jauniaux E, Alfirevic Z, Bhide AG, et al.; Royal College of Obstetricians and Gynaecologists. Placenta praevia and placenta accreta: diagnosis and management. Green-top Guideline No. 27a. BJOG. 2019;126(1):e1–e48. doi:10.1111/1471-0528.15306
  15. American College of Obstetricians and Gynecologists; Society for Maternal-Fetal Medicine. Obstetric Care Consensus No. 7: Placenta Accreta Spectrum. Obstetrics and Gynecology. 2018;132(6):e259–e275. doi:10.1097/AOG.0000000000002983 (reaffirmed 2025)
  16. American College of Obstetricians and Gynecologists. Practice Bulletin No. 181: Prevention of Rh D Alloimmunization. Obstetrics and Gynecology. 2017;130(2):e57–e70. doi:10.1097/AOG.0000000000002232 (reaffirmed 2026)
  17. American College of Obstetricians and Gynecologists. Clinical Practice Guideline No. 10: Intrapartum Fetal Heart Rate Monitoring: Interpretation and Management. Obstetrics and Gynecology. 2025;146(4):583–599. doi:10.1097/AOG.0000000000006049 (replaces the 2022 practice advisory on oxygen supplementation)